This article was published in Scientific American’s former blog network and reflects the views of the author, not necessarily those of Scientific American
On supporting science journalism
If you're enjoying this article, consider supporting our award-winning journalism by subscribing. By purchasing a subscription you are helping to ensure the future of impactful stories about the discoveries and ideas shaping our world today.
An experimental drug that works much like an ingredient in red wine and grapes kept rodents from getting fat and increased their endurance. Researchers say the drug, SIRT1720, also lowered glucose levels — good news for a human version of the medicine being developed to treat diabetes.
The findings, published in the journal Cell Metabolism, show that mice fed a high-fat diet for 10 weeks who were given 100-milligram or 500-milligram doses of the med stayed svelte; animals on the same diet that didn't receive the drug packed on the pounds. The 10 medicated mice also ran twice as long as normal rodents.
The drug works by triggering a protein called SIRT1 that normally kicks in during starvation and tells the body to burn fat and conserve energy, according to the study.
"We are activating the same enzymes that are activated when people go to the gym," Peter Elliott, an exec at Sirtris Pharmaceuticals, the Glaxo arm that developed the drug, told Reuters.
Resevatrol, an ingredient in red grapes and wine, also acts on SIRT1 by increasing sensitivity to insulin and lowering levels of glucose in the blood — anti-diabetic effects also seen in the mice who were given the experimental drug. But it took less SIRT1720 to achieve the same results.
"Resevatrol makes mice live longer and stay healthier," Elliott told Reuters. "This molecule does the same thing, but it is 1,000 times more potent so you don't need as much."
SIRT1720 is a prototype for another Sirtris drug designed for humans that also activates SIRT1. That drug, SIRT2104, is in early testing for glucose control in diabetics, says Michelle Dipp, the company's VP of corporate development. The drug is five to 10 years away from being available, she says, and would be priced the same as other once-a-day meds — about $5 to $7 per dose.
(Image by iStockphoto/Eric Isselee)
